Press Releases AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:24 2025-07-11 am EDT			5-day change	1st Jan Change
10,450.00 ^GBX	-1.66%		+1.10%	-0.17%

Jul. 11	FDA May Fast Track Drug Reviews for Lower US Prices	MT
Jul. 11	FDA May Fast Track Drug Reviews for Lower US Prices, Bloomberg Reports	MT

Press Releases

AstraZeneca - Imfinzi approved in the EU as first and only perioperative immunotherapy for muscle-invasive bladder cancer	Jul. 07	AQ
AstraZeneca : Imfinzi approved in the EU for bladder cancer	Jul. 04	PU
Modella AI Announces Agreement to Accelerate AI-Driven Oncology Clinical Development	Jul. 03	AQ
Astrazeneca CEO mulls move to shift LSE listing	Jul. 02	AQ
DATROWAY(R) Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer	Jun. 24	AQ
DATROWAY® approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer	Jun. 24	BU
Datroway approved in US for EGFRm lung cancer	Jun. 24	AQ
AstraZeneca : Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer	Jun. 23	PU
AstraZeneca : Alexion data presented at EAN 2025 highlights its leadership and commitment to improving patient outcomes in rare neurological diseases	Jun. 21	PU
Pharmacy Alert: AstraZeneca Sends "Unreserved Cooperation" Letters Demanding Farxiga® Dispensing Records	Jun. 19	AQ
AstraZeneca : enters into collaboration with CSPC	Jun. 13	PU
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU(R) Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer	Jun. 10	AQ
New tRNA tech aims to rewrite rare disease treatment	Jun. 09	AQ
AstraZeneca : Fixed-duration Calquence approved in EU for 1L CLL	Jun. 06	PU
Lumito establishes Scientific Advisory Board with leading international experts in drug development, pathology, and oncology	Jun. 05	AQ
AstraZeneca : Biographies (ASCO2025 biographies 20250602)	Jun. 03	PU
AstraZeneca : Presentation (ASCO2025 Presentation 20250602b)	Jun. 03	PU
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial	Jun. 02	BU
AstraZeneca - Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumour mutation in SERENA-6 Phase III trial	Jun. 02	AQ
AstraZeneca - Imfinzi regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial	Jun. 02	AQ
AstraZeneca : Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumour mutation in SERENA-6 Phase III trial	Jun. 01	PU
AstraZeneca : Imfinzi regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial	Jun. 01	PU
AstraZeneca unveils promising advances in breast, gastric cancer treatment	Jun. 01	AQ
IMFINZI® (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial	Jun. 01	BU
Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial	Jun. 01	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

AstraZeneca's CEO reportedly considers listing in the United States

July 02, 2025 at 03:39 am EDT

ASTRAZENECA : Sustained operational strength leads to an upgrade

May 20, 2025 at 10:42 am EDT

AstraZeneca Gets Profit Boost From Diabetes, Cancer Drugs

April 29, 2025 at 05:46 am EDT